Dialysis — Cost, Top Hospitals & Success Rates | MyMedicPlus

Dialysis is a life-sustaining kidney replacement therapy that artificially removes waste products, excess fluid, and electrolytes from the blood when the kidneys can no longer perform this function adequately. Healthy kidneys filter approximately 200 liters of blood daily, maintaining the body's chemical balance. When kidney function drops below 10–15% of normal (eGFR <15 mL/min/1.73m²), dialysis becomes necessary to prevent life-threatening accumulation of toxins, fluid overload, and electrolyte imbalances such as dangerous hyperkalemia. There are two primary forms: hemodialysis (HD), which circulates blood through an external dialysis machine via vascular access, and peritoneal dialysis (PD), which uses the peritoneal membrane as a filter inside the abdomen. Hemodialysis is typically performed three times per week at a dialysis center over 3–5 hours per session, though home hemodialysis and nocturnal dialysis (6–8 hours nightly) offer greater flexibility. The dialysis machine uses a semipermeable membrane to draw out toxins through diffusion and ultrafiltration. While dialysis does not cure kidney disease and does not replicate all kidney functions (such as hormone production), it substantially prolongs life and reduces uremic symptoms including nausea, fatigue, and cognitive impairment.

Dialysis is indicated for end-stage renal disease (ESRD) caused by diabetic nephropathy (accounting for 40% of ESRD cases globally), chronic hypertensive nephrosclerosis, IgA nephropathy, polycystic kidney disease (PKD), lupus nephritis, focal segmental glomerulosclerosis (FSGS), and rapidly progressive glomerulonephritis. Acute indications include acute kidney injury (AKI) with severe fluid overload, refractory hyperkalemia (potassium >6.5 mEq/L unresponsive to medical therapy), metabolic acidosis (pH <7.1), uremic pericarditis, uremic encephalopathy, and certain drug overdoses (e.g., lithium, methanol, ethylene glycol, salicylates). Dialysis is also bridging therapy for patients awaiting kidney transplantation. Patients with eGFR between 10–15 may begin dialysis if experiencing uremic symptoms such as nausea, vomiting, pruritus, restless leg syndrome, or inability to maintain nutritional status. Emergency dialysis is required in acute pulmonary edema unresponsive to diuretics, severe electrolyte disturbances threatening cardiac rhythm, and systemic toxin accumulation.

Dialysis candidacy is determined by nephrologists based on eGFR levels, symptom burden, and overall health status. Patients with CKD Stage 5 (eGFR <15) who are symptomatic are standard candidates. Pre-dialysis workup includes complete metabolic panel, CBC, phosphorus, parathyroid hormone, hepatitis B/C and HIV serology, ECG, chest X-ray, and vascular mapping for access planning. Vascular access must be established weeks to months before starting hemodialysis — arteriovenous fistula (AVF) is preferred as it has the lowest infection and complication rates, followed by AV graft, then tunneled central venous catheter as a last resort. Peritoneal dialysis requires intact peritoneal membrane; contraindications include prior extensive abdominal surgery causing adhesions, active inflammatory bowel disease, severe malnutrition, and inability to perform or manage the procedure. Elderly, frail patients and those with cardiovascular instability may tolerate peritoneal dialysis better than hemodialysis. Patients who decline dialysis may opt for conservative kidney management (CKM), a legitimate alternative for certain elderly or palliative patients. Shared decision-making between nephrologist, patient, and family is essential.

Dialysis management follows a structured algorithm integrating pharmacological kidney protection, dietary optimization, complication management, and preparation for kidney replacement therapy when required. Renin-angiotensin-aldosterone system (RAAS) blockade is first-line: ACE inhibitors (ramipril, perindopril) or ARBs (losartan, irbesartan, olmesartan) reduce proteinuria by 30–50% and slow GFR decline — the cornerstone of nephroprotection regardless of underlying cause; dual RAAS blockade (ACE + ARB) is no longer recommended due to adverse renal and potassium outcomes (ONTARGET trial). SGLT2 inhibitors (dapagliflozin — DAPA-CKD trial; empagliflozin — EMPA-KIDNEY trial; canagliflozin — CREDENCE trial) add 30–40% additional reduction in CKD progression and ESRD on top of RAAS blockade — now guideline first-line for all CKD patients regardless of diabetes status. Finerenone (mineralocorticoid receptor antagonist) reduces CKD progression in diabetic nephropathy — added after SGLT2 inhibitor in high-proteinuria patients. Diuretics (furosemide, torasemide) manage fluid overload and oedema in CKD Stage 4–5. Phosphate binders (calcium carbonate, sevelamer, lanthanum) prevent hyperphosphataemia-related vascular calcification in CKD Stage 3b–5. ESA therapy (erythropoietin, darbepoetin) maintains haemoglobin 10–12 g/dL. Sodium bicarbonate supplementation (500–1,000 mg twice daily) for CKD-associated metabolic acidosis (bicarbonate <22 mEq/L) slows CKD progression. Dietary: protein 0.8 g/kg/day (or lower with keto-acid supplementation in advanced CKD); sodium <2g/day; potassium restriction in hyperkalaemia.

Dialysis dramatically extends survival in ESRD patients who would otherwise die within days to weeks without treatment. The 5-year survival rate for ESRD patients on hemodialysis is approximately 35–40%, improving substantially in younger patients without diabetes or cardiovascular disease, where 10-year survival can exceed 50%. Dialysis relieves uremic symptoms — fatigue, nausea, anorexia, pruritus, mental confusion — typically within the first few sessions as toxin levels normalize. It controls fluid overload, reducing hypertension and pulmonary edema risk. Nocturnal hemodialysis (performed 5–6 nights/week) and daily short-session dialysis have demonstrated superior phosphate and fluid control, better blood pressure management, improved left ventricular mass index, and enhanced quality of life compared to conventional thrice-weekly dialysis. Peritoneal dialysis preserves residual kidney function longer than hemodialysis in many studies, which is associated with improved patient survival and quality of life. Home-based dialysis modalities (home HD, CAPD, CCPD) offer significant lifestyle advantages — no commuting to center, flexible scheduling, and independence. Many patients maintain employment and social activities during dialysis. Dietary freedom and fluid restrictions gradually ease as patients achieve stable clearance.

Hemodialysis carries access-related complications: AV fistula failure/thrombosis (25–30% within 1 year), catheter-related bloodstream infections (1–3 episodes per 1,000 catheter-days), and stenosis requiring intervention. Intradialytic hypotension (blood pressure drop during session) occurs in 20–30% of sessions, causing dizziness, cramps, and occasionally cardiac arrhythmia. Muscle cramps affect up to 50% of patients; arteriovenous access steal syndrome (limb ischemia) occurs in 1–8%. Long-term complications include cardiovascular disease (leading cause of death in dialysis patients, accounting for 50% of mortality), anemia due to reduced erythropoietin production (managed with ESAs), hyperphosphatemia, secondary hyperparathyroidism, and renal osteodystrophy. Dialysis-related amyloidosis (beta-2 microglobulin deposition) causes carpal tunnel syndrome and arthropathy after years of treatment. Peritoneal dialysis risks include peritonitis (0.5–1 episode per patient-year), PD catheter infection, catheter malposition, membrane failure (ultrafiltration failure), and encapsulating peritoneal sclerosis (rare but serious). Both modalities increase infection susceptibility due to immunosuppression associated with uremia. All dialysis patients require careful fluid, potassium, phosphate, and protein dietary management.

Regular laboratory monitoring is the cornerstone of Dialysis management. eGFR and urine albumin-to-creatinine ratio (UACR) every 3–6 months depending on CKD stage; electrolytes, bicarbonate, calcium, phosphorus, PTH, haemoglobin, and ferritin every 3–6 months in CKD Stage 3–5. Blood pressure at every clinical contact — target <130/80 mmHg. Dietary review with renal dietitian every 6 months. Fibroscan or FIB-4 annually for fibrosis progression in hepatorenal conditions. eGFR trajectory monitoring — decline >5 mL/min/year warrants intensified investigation and management. CKD Stage 4 patients require vascular access planning (AV fistula creation 3–6 months before anticipated dialysis). Annual cardiovascular risk assessment including ECG, lipid profile, and echocardiography. Medication review for nephrotoxic agents; dose adjustment for all renally cleared drugs as eGFR declines.

Nephrology treatment costs for Dialysis range from affordable outpatient medications to highly expensive renal replacement therapy. Generic RAAS blockers, SGLT2 inhibitors (generic dapagliflozin), diuretics: $10–100/month India vs $100–800/month USA. Branded nephrology drugs (finerenone, tolvaptan): $200–500/month USA; generics not yet available. Regular monitoring labs (eGFR, electrolytes, UACR, PTH, CBC): $20–80/panel India vs $200–800/panel USA. Fibroscan: $80–200 India vs $800–3,000 USA. Kidney biopsy: $500–1,500 India vs $5,000–15,000 USA. Hemodialysis: $600–1,100/month India vs $7,500–9,000/month USA. Peritoneal dialysis supplies: $400–800/month India vs $3,000–6,000/month USA. Kidney transplantation (surgery + 1 year immunosuppression): $15,000–35,000 India vs $150,000–300,000 USA — India is the leading global destination for living donor kidney transplantation for international patients. Patients should request itemized all-inclusive quotes from multiple accredited facilities to enable informed cost comparisons before committing to a treatment centre.

Conservative kidney management (CKM) is a patient-centered alternative to dialysis — appropriate for frail elderly patients where dialysis burden outweighs benefit; median survival comparable to dialysis in selected patients over 75 with multiple comorbidities. Kidney transplantation is the definitive long-term alternative to dialysis — providing near-normal quality of life, superior survival, and cardiovascular outcomes. Pre-emptive transplantation (before dialysis) achieves the best outcomes. Living donor transplantation offers 20+ year median graft survival. Dietary protein restriction (0.3–0.5 g/kg/day with keto-acid supplementation) delays dialysis initiation by 6–12 months in selected CKD Stage 4–5 patients. Stem cell therapy is investigational — mesenchymal stem cells show renoprotective potential in early clinical trials. Traditional medicine and herbal supplements (Nigella sativa, Astragalus) have limited clinical evidence and may contain nephrotoxic compounds — caution advised.